ALS (Amyotrophic Lateral Sclerosis)

ALS, or amyotrophic lateral sclerosis, is a neurological condition. The term refers to the condition as a whole, rather than to an individual symptom or treatment.

Start with a focused look at ALS (Amyotrophic Lateral Sclerosis) and its place among neurological conditions.

2What may help

This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.

What may help

None of these options has good evidence yet. Best evidence first.

2 options:2 not enough evidence

What studies foundSize of effect

Acceptance and Commitment Therapy (ACT)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
In an RCT of 191 people with ALS, quality of life improved on MQOL-R but not significantly on EQ-5D-5L. The intervention was cost-ineffective in the primary analysis but cost-effective in a subgroup with medium deterioration.
Open the Acceptance and Commitment Therapy (ACT) page
Red Light Therapy (Photobiomodulation)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A review of randomized and non-randomized human studies reported improved outcomes when photobiomodulation was combined with exercise, a magnetic field, or other agents, but one ALS study found no benefit.
Open the Red Light Therapy (Photobiomodulation) page

The expert view shows every study, dose protocol and source.

What may help

Interventions recorded as helping with this condition2 listed

The best we have, but the evidence is still weak

PracticesAcceptance and Commitment Therapy (ACT)CertaintyLowSourceClinical
In an RCT of 191 people with ALS, quality of life improved on MQOL-R but not significantly on EQ-5D-5L. The intervention was cost-ineffective in the primary analysis but cost-effective in a subgroup with medium deterioration.
Who was studied
People with a condition
Study result
RCT showing significant improvement on MQOL-R, but non-significant on EQ-5D-5L; cost-ineffective in primary analysis but cost-effective in subgroup with medium deterioration.
Open Acceptance and Commitment Therapy (ACT)
→
PracticesRed Light Therapy (Photobiomodulation)CertaintyLowSourceClinical
A review of randomized and non-randomized human studies reported improved outcomes when photobiomodulation was combined with exercise, a magnetic field, or other agents, but one ALS study found no benefit.
Who was studied
People with a condition
Als
Alzheimers Disease
Anxiety Disorder
Carpal Tunnel
Depression
Fibromyalgia
+3 more
Study result
Clinical trials and animal studies showing PBM combined with exercise, magnetic field, or other agents improved outcomes; one ALS study showed no benefit
Open Red Light Therapy (Photobiomodulation)
→

What to avoid

Interventions recorded as making it worse

Nothing in this library is currently recorded as making ALS (Amyotrophic Lateral Sclerosis) worse. Coverage is partial, and absence here is not evidence of safety.

Browse the supplements that are written up

How to read the evidence

Evidence tier — overall strength of the evidence for the whole compound

StrongWell established — backed by strong, consistent human research.
ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
LimitedVery limited evidence — treat this as a hypothesis, not proof.
InsufficientNot enough good evidence to draw conclusions yet.

Certainty — how sure we can be that the effect is real

Very highVery sure — strong, consistent evidence
HighFairly sure — consistent evidence from good studies
MediumModerately sure — new studies could change this
LowNot sure — little or mixed evidence
Very lowVery unsure — almost no usable evidence

Source — where the data comes from

Meta-analysisPooled analysis of many trials — the strongest evidence
RCTRandomized controlled trial — a strong human study design
ClinicalA human clinical study
Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
Animal researchStudied in animals, not humans
Community reportsAggregated user reports — anecdotal signal, not evidence
TheoreticalMechanism-based reasoning, not yet tested

Study grade — quality of each underlying study (A best, D weakest)

AHigh-quality — strong, consistent human trials
BGood — solid evidence with some limitations
CModerate — limited, small, or mixed-quality studies
DWeak — preliminary, indirect, or animal-only

Confidence — how strongly the sources back a finding

A 0–100 score from study quality and agreement

Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.

Full write-up

What is it

ALS, or amyotrophic lateral sclerosis, is a neurological condition. The term refers to the condition as a whole, rather than to an individual symptom or treatment. Details about its symptoms, causes, progression, and diagnosis are not provided here, so they are not expanded upon. Questions about ALS and treatment options are appropriate to discuss with a clinician.

Evidence-backed options

No evidence-backed options are listed here for ALS (Amyotrophic Lateral Sclerosis). For information about treatment or supportive care, consult a qualified clinician who can consider the individual circumstances.

What to avoid

BCAA supplements are flagged for avoidance in amyotrophic lateral sclerosis (ALS) because a clinical trial in people with ALS found that supplementation was associated with increased mortality. Based on this finding, BCAA supplements are considered contraindicated for people with ALS.

This concern applies specifically to ALS and reflects an observed safety signal in a clinical trial, rather than a general statement about BCAA use in every condition. Anyone with ALS should discuss supplements with a clinician before using them, particularly when treatment decisions may affect safety.